SHSimone Bega Harnik

Simone Bega Harnik

Universidade de São Paulo
*This is an algorithmically generated author record based on publicly available information.
See Latest Publications
See Most Cited Publications
ORCID Profile
Google Scholar

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Simone Bega Harnik has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Bruna Letícia de Souza Lima

    ADJ Diabetes Brasil (ADJ), Rua Padre Antônio Tomás, 213, Zip Code 05003-010, Água Branca, São Paulo, SP, Brazil; Fórum Intersetorial para Combate às DCNTs no Brasil (ForumDCNTs), Rua Padre Antônio Tomás, 213, Zip Code 05003-010, Água Branca, São Paulo, SP, Brazil

    2 shared publications
  • Mark Thomaz Ugliara Barone

    Intersectoral Forum of NCCs/NCDs in Brazil (ForumCCNTs), São Paulo, SP, Brazil

    2 shared publications

  • Patrícia Vieira de Luca

    Fórum Intersetorial para Combate às DCNTs no Brasil (ForumDCNTs), Rua Padre Antônio Tomás, 213, Zip Code 05003-010, Água Branca, São Paulo, SP, Brazil; Associação Brasileira de Hipercolesterolemia Familiar (AHF), Rua Machado Bittencourt 190, Vila Clementino, Zip Code 04044-000, São Paulo, Brazil

    2 shared publications

  • Ronaldo José Pineda Wieselberg

    International Diabetes Federation (IDF), 166 Chaussee de La Hulpe B-1170, Brussels, Belgium; ADJ Diabetes Brasil (ADJ), Rua Padre Antônio Tomás, 213, Zip Code 05003-010, Água Branca, São Paulo, SP, Brazil; Fórum Intersetorial para Combate às DCNTs no Brasil (ForumDCNTs), Rua Padre Antônio Tomás, 213, Zip Code 05003-010, Água Branca, São Paulo, SP, Brazil; Sociedade Brasileira de Diabetes (SBD), Rua Afonso Braz 579, Salas 72/74, Vila Nova Conceição, Zip Code 04511-011, São Paulo, SP, Brazil

    2 shared publications

  • Viviana Giampaoli

    Universidade de São Paulo, Instituto de Matemática e Estatística, Departamento de Estatística, Rua do Matão 1010, Cidade Universitária, Zip Code 05508-090 São Paulo, SP, Brazil

    2 shared publications

  • Augusto Pimazoni-Netto

    Sociedade Brasileira de Diabetes (SBD), Rua Afonso Braz 579, Salas 72/74, Vila Nova Conceição, Zip Code 04511-011, São Paulo, SP, Brazil; Hospital do Rim e Hipertensão - Centro de Hipertensão e Metabologia Cardiovascular, Grupo de Educação e Controle do Diabetes, Rua Leandro Dupret, 365, Vila Clementino, Zip Code 04025-011, São Paulo, SP, Brazil

    1 shared publication

Latest Publications

  • Website
    Google Scholar

    The impact of COVID-19 on people with diabetes in Brazil

    by Mark Thomaz Ugliara Barone, Simone Bega Harnik, Patrícia Vieira de Luca, Bruna Letícia de Souza Lima, Ronaldo José Pineda Wieselberg, Belinda Ngongo, Hermelinda Cordeiro Pedrosa, Augusto Pimazoni-Netto, Denise Reis Franco, Maria de Fatima Marinho de Souza, et al.

    Cited by 84
  • Website
    Google Scholar

    COVID-19 impact on people with diabetes in South and Central America (SACA region)

    by Mark Thomaz Ugliara Barone, Douglas Villarroel, Patrícia Vieira de Luca, Simone Bega Harnik, Bruna Letícia de Souza Lima, Ronaldo José Pineda Wieselberg, Viviana Giampaoli

    Cited by 34
  • Website
    Google Scholar
    Open Access

    Neuropathic pain in leprosy: symptom profile characterization and comparison with neuropathic pain of other etiologies

    by Irina Raicher, Patrick Raymond Nicolas Andre Ghislain Stump, Simone Bega Harnik, Rodrigo Alves de Oliveira, Rosemari Baccarelli, Lucia H.S.C. Marciano, Somei Ura, Marcos C.L. Virmond, Manoel Jacobsen Teixeira, Daniel Ciampi de Andrade

    Introduction: Previous studies reported a high prevalence of neuropathic pain in leprosy, being especially present in “pharmacologically cured” patients. The presence of neuropathic pain in leprosy poses a supplementary burden in patient's quality of life, daily activities, and mood.Objectives: The aim of this study was to assess whether neuropathic pain in leprosy has similar symptom profile as neuropathic pain of other etiologies and to retrospectively assess the efficacy of neuropathic pain medications regularly prescribed to leprosy.Methods: Leprosy and nonleprosy patients had their neuropathic pain characterized by the neuropathic pain symptom inventory (NPSI, ranges from 0 to 100, with 100 being the maximal neuropathic pain intensity) in a first visit. In a second visit, leprosy patients who had significant pain and received pharmacological treatment in the first evaluation were reassessed (NPSI) and had their pain profile and treatment response further characterized, including information on drugs prescribed for neuropathic pain and their respective pain relief.Results: The pain characteristics based on NPSI did not significantly differ between leprosy and nonleprosy neuropathic pain patients in visit 1 after correction for multiple analyses, and cluster analyses confirmed these findings (ie, no discrimination between leprosy and nonleprosy groups; Pearson χ2 = 0.072,P= 0.788). The assessment of pain relief response and the drugs taken by each patient, linear regression analysis showed that amitriptyline, when effective, had the highest percentage of analgesic relief.Conclusions: Neuropathic pain in leprosy is as heterogeneous as neuropathic pain of other etiologies, further supporting the concept that neuropathic pain is a transetiological entity. Neuropathic pain in leprosy may respond to drugs usually used to control pain of neuropathic profile in general, and amitriptiline may constitute a potential candidate drug for future formal clinical trials aimed at controlling neuropathic pain in leprosy.

    Cited by 26